Regen BioPharma Inc (RGBP) — SEC Financial Statements & Analysis

Regen BioPharma Inc (RGBP) is a pharmaceutical preparations company, incorporated in NV. Regen BioPharma Inc trades on OTC as: RGBP, RGBPP. Regen BioPharma Inc (RGBP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-17. Based on that filing, Regen BioPharma Inc carries a market cap of $123.11K, a P/E ratio of -0.10x, a P/B ratio of -0.02x, a P/S ratio of 0.52x, an enterprise value of $122.87K, and an EV/EBITDA multiple of -0.15x. On profitability, it posts a gross margin of 121.95%, an operating margin of -339.81%, a net margin of -509.61%, a Return on Equity (ROE) of 20.62%, and a Return on Assets (ROA) of -497.72%. Per share, it reports EPS of $-0.00, diluted EPS of $-0.00, free cash flow per share of $-0.00, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 0.00% year-over-year, net income growth of 56.98% year-over-year, and EPS growth of -93.94% year-over-year. On the balance sheet, it maintains a current ratio of 0.05x, a quick ratio of 0.05x, working capital of $-5.88M, a debt-to-equity ratio of -1.05x, a debt ratio of 21.44, an interest coverage ratio of -4.72x, free cash flow of $-445.25K (TTM), and net debt of $-239. Figures sourced from SEC EDGAR.

Market Cap

$123.11K

P/E TTM

-0.10x

EPS TTM

$-0.00

P/B TTM

-0.02x

ROE TTM

20.62%

ROA TTM

-497.72%

Debt To Equity

-1.05x

Free Cash Flow TTM

$-445.25K

Net Revenue TTM Growth 1Y

0.00%

Data as of 2026-06-30 · Source: SEC EDGAR